2023
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S, Moutier C, Rush A, Johnson G, Tal I, Chen P, Davis L, Hicks P, Wilcox J, Planeta B, Lauro K, Scrymgeour A, Kasckow J, Mohamed S. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine 2023, 54: 1172-1183. PMID: 37859623, DOI: 10.1017/s0033291723003008.Peer-Reviewed Original ResearchMajor depressive disorderNext-step treatmentsLifetime suicidal ideationSuicidal ideationSuicide riskLower positive mental healthPrevalence of SISevere depressive episodeAcute treatment periodCurrent MDD episodeBaseline suicidal ideationMore childhood adversitiesSuicide prevention interventionsRisk of SICurrent suicidal ideationAntidepressant treatmentMost patientsInitial medicationMDD episodeMedication treatmentDepressive episodeDepressive disorderTreatment periodDepression trialsPrevention interventionsFactors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Zisook S, Mohamed S. Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. Psychiatric Research And Clinical Practice 2023, 5: 131-143. PMID: 38077276, PMCID: PMC10698706, DOI: 10.1176/appi.prcp.20230017.Peer-Reviewed Original ResearchGroup-based trajectory modelingBaseline depressionEarly improvementSwitching treatmentSingle-blind trialHigher baseline depressionDepression symptom changeAdditional exploratory analysesAssociation of treatmentMajor depressive disorderLogistic regression analysisDepression Outcomes studyDemographic factorsMultinomial logistic regression analysisSpecific depression symptomsExploratory analysisProbability of responseAntidepressant trialsSeverity scoreDepressive disorderTrial reportsOutcome studiesBaseline anxietyPrimary analysisTreatment interventions
2022
Childhood adversity and adulthood major depressive disorder
Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022, 76: 36-44. PMID: 35366613, DOI: 10.1016/j.genhosppsych.2022.03.008.Peer-Reviewed Original ResearchConceptsMajor depressive disorderChildhood adversityDepressive disorderSuicidal ideationLower remission rateLower depression severityDepression Outcomes studyMore lifetime episodesGOV IDENTIFIERRemission rateClinical featuresClinical outcomesSevere depressionTreatment strategiesLifetime episodesOutcome studiesDepression severitySwitching treatmentYounger ageSecondary analysisComorbid PTSDChildhood maltreatmentWorse qualitySpecific typesDisorders
2020
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
Zisook S, Johnson G, Hicks P, Chen P, Beresford T, Michalets J, Rao S, Thase M, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report. Depression And Anxiety 2020, 38: 185-195. PMID: 33225492, DOI: 10.1002/da.23114.Peer-Reviewed Original ResearchConceptsDepressive symptom severityContinuation treatmentBupropion SRTreatment outcomesTreatment-resistant major depressive disorderSymptom severitySignificant differential treatment effectsContinuation treatment phaseAcute-phase treatmentAbnormal laboratory valuesLower relapse rateMajor depressive disorderQuality of lifeLess anxietyDifferential treatment effectsMore somnolenceDry mouthRelapse rateExtrapyramidal effectsFull remissionWeek 12Continuation phaseTreatment attemptsDepressive disorderLaboratory valuesStages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study
Rhee TG, Mohamed S, Rosenheck RA. Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study. Journal Of Affective Disorders 2020, 278: 443-452. PMID: 33010569, DOI: 10.1016/j.jad.2020.09.081.Peer-Reviewed Original ResearchConceptsChronic major depressive disorderMajor depressive disorderNew-onset major depressive disorderOnset major depressive disorderBorderline personality disorderDepressive disorderUse disordersRepresentative cross-sectional surveyRepresentative epidemiologic studyPersonality disorderMore psychiatric disordersSubstance use disordersAlcohol use disorderNational Epidemiologic SurveyRelated Conditions-IIICross-sectional surveyDSM-5 diagnostic criteriaMultivariable analysisGroup of adultsEpidemiologic studiesUS adultsDiagnostic criteriaPsychiatric disordersEpidemiologic SurveyMDD historyImpact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Mohamed S, Zisook S. Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report. Psychiatric Research And Clinical Practice 2019, 1: 58-67. PMID: 36101874, PMCID: PMC9176018, DOI: 10.1176/appi.prcp.20190003.Peer-Reviewed Original ResearchNegative predictive valuePositive predictive valueEarly improvementWeek 2Antidepressant therapyAntidepressant treatmentPredictive valueSingle-blind trialDepressive Symptomatology-Clinician RatedMajor depressive disorderDepression Outcomes studyWeek 12Medication interventionsQuick InventoryDepressive disorderWeek 6Trial reportsOutcome studiesTreatment groupsDegree of improvementSwitching treatmentClinical decisionSecondary analysisRemissionMinimal improvementGeneral Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
2016
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideation
2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original Research
2012
Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?
Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? Neuropsychobiology 2012, 65: 168-172. PMID: 22456094, PMCID: PMC3701889, DOI: 10.1159/000331141.Peer-Reviewed Original ResearchConceptsSchizoaffective disorderCognitive deficitsDepression Rating Scale scoresHamilton Depression Rating ScaleFlexible-dose treatmentAntidepressant treatment responseDepression Rating ScaleTreatment of depressionMajor depressive disorderRating Scale scoresBaseline cognitive statusPlacebo groupAntidepressant medicationCurrent medicationsPlacebo augmentationFunctional disabilityCognitive composite scoreSubsyndromal depressionDepressive disorderSubsyndromal symptomsTreatment responseTreatment groupsDose treatmentScale scoreCognitive status
2009
Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. The Journal Of Clinical Psychiatry 2009, 70: 906-12. PMID: 19422760, DOI: 10.4088/jcp.08m04450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntidepressive AgentsAntipsychotic AgentsComorbidityDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDrug UtilizationFemaleHospitals, VeteransHumansMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationVeteransConceptsMajor depressive disorderTreatment of MDDAntipsychotic medicationDepressive disorderService useMental health service useVeterans Affairs patientsUse of antipsychoticsHealth service useComorbid mental illnessDrug Administration approvalLong-term safetyRecent U.S. FoodFirst antipsychoticAntipsychotic dosesAntipsychotic prescriptionsPsychiatric comorbidityComorbid schizophreniaMale genderAdministration approvalVeteran characteristicsMedicationsSchizoaffective disorderAntipsychoticsBipolar disorder
2008
Pharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans
Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans. Psychiatric Services 2008, 59: 1184-1190. PMID: 18832505, DOI: 10.1176/ps.2008.59.10.1184.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPsychotropic medicationsMedication classesStress disorderTreatment of PTSDMental health care usersSymptom-specific responsesComorbid psychiatric disordersUse of anxiolyticsMultivariate logistic regressionDiagnosis of PTSDMajor depressive disorderMental health servicesHealth care usersMedication usePharmacologic treatmentAntidepressant useHealth insurance plansMarketScan databaseAntipsychotic usePrivate health insurance plansPharmacological treatmentDepressive disorderSpecific symptomsMillions of AmericansPharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection.
Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. The Journal Of Clinical Psychiatry 2008, 69: 959-65. PMID: 18588361, DOI: 10.4088/jcp.v69n0611.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Anxiety AgentsAntipsychotic AgentsAnxietyComorbidityDrug TherapyFemaleHumansHypnotics and SedativesInternational Classification of DiseasesMaleMiddle AgedPsychotropic DrugsSleep Initiation and Maintenance DisordersStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsConceptsPosttraumatic stress disorderAnxiolytic/Psychotropic medicationsVeterans AffairsMedication classesService usePharmacotherapy of PTSDMental health service useTreatment of PTSDGreater mental health service usePsychotropic medication classesSedative-hypnotic useHealth service useMultivariable logistic regressionAntidepressant useMedication usePsychotropic prescriptionsAntipsychotic useSuch medicationsVA patientsPsychotropic pharmacotherapySymptom responseDepressive disorderVeteran characteristicsSpecific symptoms